Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

Many parents said they were afraid of noninvasive ventilation, with some citing inaccurate concerns about ventilation devices.

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

The bank's head of blockchain solutions Philippe Meyer told the DigiAssets conference in London that it started advising on ...